Most NCDs could be treated with small number of cheap generic drugs and within existing budgets

In the fifth Series paper, researchers led by Professor Hans Hogerzeil from the University of Groningen in the Netherlands say that most NCDs could be treated with a small range of inexpensive, off-patent medicines, and suggest that substantial improvements in availability of life-saving drugs in poorer nations could be achieved within existing budgets by more careful selection and sourcing of generic versions, and better targeting of people at highest risk.

They point to examples such as: generic insulin that could be made available in many low-income and middle-income countries at prices five to eight times cheaper that those currently paid for newer and branded products; and multidrug regimens for people at high- that could cost as little as US$1 per head per year and prevent 18 million deaths in 23 of the poorest nations over the next 10 years.

However, they say, better selection and procurement policies alone will not be enough to make life-saving medicines and vaccines affordable to all people that need them.

They outline several other key measures including: increased investment from domestic sources through tax-based or obligatory health-insurance; integrating drug management within existing initiatives for HIV/AIDS to achieve uninterrupted availability of NCD drugs and adherence to long-term treatment; increasing the unacceptable low availability of opioid medication for ; and coherent and equitable health and trade policies to guarantee access to newer, patented drugs.

"Access to medicines and vaccines to prevent and treat NCDs is unacceptably low worldwide. Only with these approaches [outlined in this paper] can a difference be made to the lives of hundreds of millions of current and future patients with NCDs", they conclude.

More information: www.thelancet.com/series/non-communicable-diseases

add to favorites email to friend print save as pdf

Related Stories

More AIDS patients may get cheaper drugs

Jul 12, 2011

(AP) -- Gilead Sciences Inc. will allow some of its AIDS drugs to be made by generic manufacturers, potentially increasing their availability in poor countries, particularly in Africa, officials said Tuesday.

Non-communicable diseases having devastating global impact

Aug 30, 2012

Non-communicable diseases (NCDs) such as heart disease, cancer and diabetes are no longer just a problem in wealthy nations – the rate of NCDs in low-to-middle income countries are increasing faster than in developed countries.

Recommended for you

Supercomputers link proteins to drug side effects

16 hours ago

New medications created by pharmaceutical companies have helped millions of Americans alleviate pain and suffering from their medical conditions. However, the drug creation process often misses many side ...

No added benefit proven for umeclidinium/vilanterol in COPD

Oct 20, 2014

The drug combination umeclidinium/vilanterol (trade name Anoro) has been approved since May 2014 for adults with chronic obstructive pulmonary disease (COPD). In an early benefit assessment pursuant to the Act on the Reform ...

User comments